VJVirtual | Updated results from the CASPIAN trial of durvalumab plus chemo in SCLC

Robin Cornelissen, MD, PhD, Erasmus University Medical Center, Rotterdam, The Netherlands, discusses the results of the randomized Phase III CASPIAN trial (NCT03043872) of durvalumab, with or without tremelimumab, and platinum-etoposide chemotherapy, versus platinum-etoposide alone in extensive-stage small-cell lung cancer (ES-SCLC). Previously published results demonstrated a significant overall survival (OS) prolongation in the durvalumab plus chemotherapy arm compared to chemotherapy alone. Updated results were recently published in The Lancet Oncology, including an analysis of the third trial arm of durvalumab, tremelimumab and chemotherapy. After a median follow-up of over 25 months, the OS improvement with durvalumab plus chemotherapy was sustained. However, the addition of tremelimumab to durvalumab and chemotherapy did not significantly improve outcomes compared to chemotherapy alone. The long-term benefit seen with durvalumab plus platinum–etoposide supports its development as a new standard of care for ES-SCLC. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.